Holger Hof1, Thomas Welzel, Jürgen Debus. 1. Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. holger.hof@med.uni-heidelberg.de
Abstract
BACKGROUND: Chordomas are rare tumors of the skull base and the spine. Treatment is difficult since conventional radiotherapy or chemotherapy have only limited effects. PATIENT AND METHODS: A patient with a sacral chordoma and pulmonary metastases received initial surgery and radiotherapy for a local recurrence. After 11 months another local recurrence as well as a progression of the pulmonary metastases was documented. As tumor biopsies revealed the expression of the EGF receptor an individual treatment approach with a combination of cetuximab and gefitinib was performed. RESULTS: Under the treatment with cetuximab/gefitinib the local recurrence and the pulmonary metastases showed a partial response over the follow-up period of 9 months. To date no treatment failure was observed. CONCLUSIONS: The inhibition of the EGF pathway seems to be an effective measure in the treatment of a chordoma. Further follow-up will have to prove the long-term efficiency.
BACKGROUND:Chordomas are rare tumors of the skull base and the spine. Treatment is difficult since conventional radiotherapy or chemotherapy have only limited effects. PATIENT AND METHODS: A patient with a sacral chordoma and pulmonary metastases received initial surgery and radiotherapy for a local recurrence. After 11 months another local recurrence as well as a progression of the pulmonary metastases was documented. As tumor biopsies revealed the expression of the EGF receptor an individual treatment approach with a combination of cetuximab and gefitinib was performed. RESULTS: Under the treatment with cetuximab/gefitinib the local recurrence and the pulmonary metastases showed a partial response over the follow-up period of 9 months. To date no treatment failure was observed. CONCLUSIONS: The inhibition of the EGF pathway seems to be an effective measure in the treatment of a chordoma. Further follow-up will have to prove the long-term efficiency.
Authors: Wesley Hsu; Thomas A Kosztowski; Hasan A Zaidi; Michael Dorsi; Ziya L Gokaslan; Jean-Paul Wolinsky Journal: Curr Treat Options Oncol Date: 2009-06-23
Authors: Adrian von Witzleben; Lukas T Goerttler; Jochen Lennerz; Stephanie Weissinger; Marko Kornmann; Regine Mayer-Steinacker; Alexandra von Baer; Markus Schultheiss; Peter Möller; Thomas F E Barth Journal: Eur Spine J Date: 2015-09-23 Impact factor: 3.134
Authors: Anthony C Wang; John H Owen; Waleed M Abuzeid; Shawn L Hervey-Jumper; Xiaobing He; Mikel Gurrea; Meijuan Lin; David B Altshuler; Richard F Keep; Mark E Prince; Thomas E Carey; Xing Fan; Erin L McKean; Stephen E Sullivan Journal: J Neurol Surg B Skull Base Date: 2016-05-31